Anatomically realistic nasal replicas capturing the range of nasal spray drug delivery in adults

被引:11
|
作者
Alfaifi, Ali [1 ]
Hosseini, Sana [1 ]
Esmaeili, Amir R. [1 ]
Walenga, Ross [2 ]
Babiskin, Andrew [2 ]
Schuman, Theodore [3 ]
Longest, Worth [1 ,4 ]
Hindle, Michael [4 ]
Golshahi, Laleh [1 ]
机构
[1] Virginia Commonwealth Univ, Dept Mech & Nucl Engn, Richmond, VA 23284 USA
[2] US FDA, Ctr Drug Evaluat & Res, Div Quantitat Methods & Modeling, Off Res & Stand, Silver Spring, MD USA
[3] VCU Hlth, Dept Otolaryngol Head & Neck Surg, Richmond, VA USA
[4] Virginia Commonwealth Univ, Dept Pharmaceut, Richmond, VA USA
关键词
Nasal spray; Regional deposition; Anatomical variability; Bioequivalence; Locally-acting drugs; In vitro aerosol testing; DEPOSITION; PHYSIOLOGY; ANATOMY; NOSE; VARIABILITY; PARTICLES; PATTERNS; PUMPS;
D O I
10.1016/j.ijpharm.2022.121858
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To improve the relationships between commonly conducted in vitro studies for locally-acting nasal spray drug products with in vivo regional deposition, this study developed a set of in vitro adult nasal geometries that captured the range of nasal drug delivery to the region posterior to internal nasal valve (INV), also known as posterior delivery (PD), and evaluated their performance with existing in vivo data. The PD of fluticasone propionate (FP) and fluticasone furoate (FF) in 40 nasal cavities was statistically analyzed to identify three airway models representing the low, mean, and high PD in adults. The models were also externally validated by comparing the in vitro nasal deposition from a different drug product (mometasone furoate (MF)) with the relevant in vivo data. The three selected geometries represented the low, mean, and high PD with multiple nasal sprays. They were verified in terms of reproducibility of in vitro data and validated by showing a reasonable agreement with preexisting in vivo MF PD despite differences in administration and defining the regions. The three models are envisioned to potentially facilitate the development of locally-acting nasal sprays and provide a better understanding of how in vitro metrics relate to in vivo regional nasal deposition.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Nasal Inserts for Drug Delivery: An Overview
    Algin-Yapar, Evren
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2014, 13 (03) : 459 - 467
  • [42] Absorption enhancers for nasal drug delivery
    Davis, SS
    Illum, L
    CLINICAL PHARMACOKINETICS, 2003, 42 (13) : 1107 - 1128
  • [43] Nasal drug delivery of sumatriptan succinate
    Chavanpatil, MD
    Vavia, PR
    PHARMAZIE, 2005, 60 (05): : 347 - 349
  • [44] Prodrug strategies in nasal drug delivery
    Pezron, I
    Tirucherai, GS
    Duvvuri, S
    Mitra, AK
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2002, 12 (03) : 331 - 340
  • [45] Permeability issues in nasal drug delivery
    Arora, P
    Sharma, S
    Garg, S
    DRUG DISCOVERY TODAY, 2002, 7 (18) : 967 - 975
  • [46] NASAL DRUG DELIVERY- AN OVERVIEW
    Mundlia, Jyoti
    Kumar, Mukesh
    Amardeep
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2015, 6 (03): : 951 - 960
  • [47] Absorption Enhancers for Nasal Drug Delivery
    Stanley S. Davis
    Lisbeth Illum
    Clinical Pharmacokinetics, 2003, 42 : 1107 - 1128
  • [48] Comparison of Budesonide Delivery Via Nasal Spray and a Nasal Nebulizer to an In Vitro Adult Model
    Nagel, M.
    Rotenberg, B. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [49] MICROSPHERES AS A NASAL DRUG DELIVERY SYSTEM
    ILLUM, L
    DAVIS, SS
    FARAJ, N
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1987, 76 (11) : S74 - S74
  • [50] Nasal and pulmonary drug delivery systems
    Martini, A
    Muggetti, L
    Warchol, MP
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (03) : 315 - 323